4 ms·

This too is my recollection of the initial clinical trial results — shortened course of disease but no indication of improved survival. The new WHO study reinfo

This too is my recollection of the initial clinical trial results — shortened course of disease but no indication of improved survival. The new WHO study reinforces the initial evidence but is not new news. Edit: The closest Gilead has come to suggesting a survival advantage from Remdesivir was a comparative analysis presented in July [1]. The analysis was highlighted as inconclusive because it wasn’t a double-blinded placebo-controlled study, which is the gold standard for clinical trials. [1]: https://www.bloomberg.com/news/articles/2020-07-10/gilead-s-remdesivir-linked-to-62-reduction-in-mortality-risk https://www.bloomberg.com/news/articles/2020-07-10/gilead-s-...

koheripbal 6y ago
The biggest limitation to this drug is that it probably works very well IF given in the first 12 hours of infection when viral replication is highest. The problem is that since it's intravenous, it's hard to justify giving it to people BEFORE they seem sick. Naturally patients and doctors are pressured to treat the sickest patients first, and so they get the Remdesivir, despite it likely not doing much so late in sickness. Ideally, if we could identify people highest at risk, and early in their disease - THEY should be given the drug very rapidly. ...but again, without that identification step, it's very hard to justify giving someone an experimental treatment.